Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | PYGB | P11216 | 7/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28378672 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL12894485 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL2230624 | 1.00 | CA12 (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL31510868 | 0.84 | CA12 (0.49) | CA12CA1CA2CA9PYGB | |
| SCHEMBL14067604 | 0.82 | CA1 (0.59) | CA12CA1CA2CA9PYGB | |
| SCHEMBL12603813 | 0.82 | CA12 (0.55) | CA12CA1CA2CA9PYGB | |
| SCHEMBL14707760 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL18722237 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL1647661 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB | |
| SCHEMBL3228008 | 0.82 | PYGB (0.58) | CA12CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831847-B1 | METHOD OF SYNTHESIS OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS | BIODYNAMICS PHARMACEUTICALS IN (US) | 2005-03-09 | — | — | EP | claimed |
| US-6770635-B1 | A DIGLUCOSYLAMINE | PHAROS PHARMACEUTICALS | 2004-08-03 | — | — | US | claimed |
| EP-0831847-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | Biodynamics Pharmaceuticals, Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5631245-A | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | claimed |
| WO-1996039153-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-9045523-B2 | Compounds | PHAROS PHARMACEUTICALS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2144920-B1 | Sulphated amino sugars with anti-inflammatory properties | DIOSAMINE DEV CORP (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2586786-A1 | Sulphated amino sugars with anti-inflammatory properties | Diosamine Development Corporation (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20110044901-A1 | NOVEL COMPOUNDS | DIOSAMINE DEVELOPMENT CORPORATION (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2144920-A1 | NOVEL COMPOUNDS | Diosamine Development Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008152421-A2 | MODIFICATION OF CYTOKINE LEVELS WITH GLUCOSYLAMINE COMPOUNDS | DIOSAMINE DEVELOPMENT CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008059003-A1 | NOVEL COMPOUNDS | DIOSAMINE DEVELOPMENT CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| CN-1190891-A | Use of di-beta-D-glucopyranosylamine compounds for controlling inflammatory reactions, and method of systnesis | BIODYNAMICS PHARMACEUTICALS IN (US) | 1998-08-19 | — | — | CN | disclosed |
| EP-0831847-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | Biodynamics Pharmaceuticals, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0831847-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | Biodynamics Pharmaceuticals, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5631245-A | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5631245-A | Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| WO-1996039153-A3 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS IN (US) | 1997-03-27 | — | — | WO | disclosed |
| WO-1996039153-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039153-A2 | USE OF DI-BETA-D-GLUCOPYRANOSYLAMINE COMPOUNDS FOR CONTROLLING INFLAMMATORY REACTIONS, AND METHOD OF SYNTHESIS | BIODYNAMICS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044901-A1 | NOVEL COMPOUNDS | AREG, CCL2, CRH | CA12 1275/4885CA1 2752/4885CA2 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.